Newsroom

Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors One patient experienced a complete response, and one patient had a partial response This type of cancer has limited treatment options, and most patients have a poor prognosis of six months or less AIC100 is a CAR T cell therapy that targets the ICAM-1 protein...

RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors  Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies  Encouraging early results in this first-in-human trial prompted additional trial cohorts...